OTHER GROUP COMPANIES
market

Aurobindo Pharma stock dips over 4% after Hyderabad-based unit 1 receives USFDA warning letter for OAI classification

Aurobindo said it will be engaging with the regulator and is fully committed to resolving this issue at the earliest.

January 14, 2022 12:22 IST | India Infoline News Service
Aurobindo Pharma has received a warning letter from the USFDA for the OAI classification of the company's Unit I, an API manufacturing facility in Hyderabad.

In its regulatory filing today, Aurobindo said that this action follows the recent inspection of the Unit by the USFDA in August 2021. The Company believes that this will not impact the existing business from this facility.

Aurobindo said it will be engaging with the regulator and is fully committed to resolving this issue at the earliest. The Company is also committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe.

At around 12.18 pm, Aurobindo was trading at Rs688.35 per piece down by Rs29.55 or 4.12% on Sensex.

The stock has touched an intraday high and low of Rs705 per piece and Rs684.50 per piece respectively. 

OPEN A DEMAT ACCOUNT & Get FREE Benefits worth 10,000

OPEN A DEMAT ACCOUNT & Get
FREE Benefits worth 10,000

STOCK VIEW

PRESTIGE (NSE)

The average score for Prestige Estates Projects Limited stands at 4 against 6, three months back.

Prestige Estates Projects Limited is engaged in the business of real estate development. The Company’s principal products/services include Development and construction

FEATURED ARTICLE

BLOGS

Open ZERO Brokerage Demat Account

  • 0

    Delivery Brokerage for Lifetime

  • 20

    Per order for Intraday, F&O, Currency & Commodity